Abstract: RAI GuidePx: A robust predictor for radioactive iodine sensitivity status in papillary thyroid cancer leveraging thyroid differentiation genes.

Abstract: 0539American Thyroid Association Annual MeetingOct 30 – Nov 3, 2024This is early work describing the development of an algorithm for predicting resistance to RAI. The internal validation is excellent,…

Continue ReadingAbstract: RAI GuidePx: A robust predictor for radioactive iodine sensitivity status in papillary thyroid cancer leveraging thyroid differentiation genes.

Abstract: Molecular subtypes in radiation induced papillary thyroid cancer using Thyroid GuidePx.

Abstract: 0551American Thyroid Association Annual MeetingOct 30 - Nov 3, 2024Here we wanted to explore whether the biology captured by our prognostic test, Thyroid GuidePx, was present in radiation induced…

Continue ReadingAbstract: Molecular subtypes in radiation induced papillary thyroid cancer using Thyroid GuidePx.

Understanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges

Understanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges Radioactive iodine (RAI) therapy is a common and effective treatment for thyroid cancer. However, in some cases, patients may not…

Continue ReadingUnderstanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges

Navigating Thyroid Cancer Treatments: Papillary vs. Follicular Subtypes

Navigating Thyroid Cancer Treatments: Papillary vs. Follicular Subtypes Thyroid cancer is a complicated disease that needs individualized treatment methods. There are two main types of differentiated thyroid cancer: papillary thyroid…

Continue ReadingNavigating Thyroid Cancer Treatments: Papillary vs. Follicular Subtypes